Drupal.behaviors.print = function(context) {window.print();window.close();}>
Alnylam Provides Timelines for Drug Programs, Offers No Formal Guidance on Partnerships
February 16, 2012
Alnylam Provides Timelines for Drug Programs, Offers No Formal Guidance on Partnerships
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Alnylam Focuses on Two Lead Programs, Won't Advance Others without Partners
January 12, 2012 / Gene Silencing News
Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News
Tekmira to Present Cancer Drug Data at AACR, Aims for Phase II by Year-End
March 28, 2013 / Gene Silencing News
Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs
February 14, 2013 / Gene Silencing News
Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News